U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C12H15NO3S
Molecular Weight 253.317
Optical Activity ( + )
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Thiorphan, (S)-

SMILES

OC(=O)CNC(=O)[C@@H](CS)CC1=CC=CC=C1

InChI

InChIKey=LJJKNPQAGWVLDQ-SNVBAGLBSA-N
InChI=1S/C12H15NO3S/c14-11(15)7-13-12(16)10(8-17)6-9-4-2-1-3-5-9/h1-5,10,17H,6-8H2,(H,13,16)(H,14,15)/t10-/m1/s1

HIDE SMILES / InChI

Molecular Formula C12H15NO3S
Molecular Weight 253.317
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Thiorphan is the first potent synthetic inhibitor of enkephalinase. Thiorphan displays antinociceptive activity after systemic administration. Thiorphan also inhibits to a lesser extent the widely distributed angiotensin-converting enzyme, a carboxydipeptidase implicated in blood pressure regulation. Thiorphan failed to potentiate allergen-induced airway responses in asthma. Thiorphan significantly reduced the castor oil-induced diarrhea in rats when administered intravenously but not when administered intracerebroventricularly. Racecadotril, via its active metabolite thiorphan, was consistently effective in animal models and patients with various forms of acute diarrhea by inhibiting pathologic (but not basal) secretion from the gut without changing gastro-intestinal transit time or motility.

CNS Activity

Curator's Comment: Ecadotril ((S)-acetorphan) is CNS active in animals when administered parenterally. No human data available.

Originator

Curator's Comment: Roques, B. P., Schwartz, J. C. & Lecomte, J. M., inventors. Derives d'acides amines et leur application therapeutique. Fr. Pat. 8008601, Apr. 17, 1980; Eur. Pat. Appl. EP 38,758; Apr. 14, 1981.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Palliative
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Doses

Doses

DosePopulationAdverse events​
400 mg 2 times / day multiple, oral
Highest studied dose
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Other AEs: Dizziness, Headache...
Other AEs:
Dizziness (grade 1-2, 35%)
Headache (16%)
Insomnia (6%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Headache 16%
400 mg 2 times / day multiple, oral
Highest studied dose
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Insomnia 6%
400 mg 2 times / day multiple, oral
Highest studied dose
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Dizziness grade 1-2, 35%
400 mg 2 times / day multiple, oral
Highest studied dose
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice.
1980 Nov 20
Thiorphan potentiation of stress-induced analgesia in the mouse.
1982 Sep 20-27
Complete differentiation between enkephalinase and angiotensin-converting enzyme inhibition by retro-thiorphan.
1983 Jun
Pharmacological properties of acetorphan, a parenterally active "enkephalinase" inhibitor.
1986 Jun
Naloxone-reversible antidiarrheal effects of enkephalinase inhibitors.
1987 Dec 1
Attenuation of the morphine withdrawal syndrome by inhibition of catabolism of endogenous enkephalins in the periaqueductal gray matter.
1992 Apr
Role of neutral endopeptidase in exercise-induced bronchoconstriction in asthmatic subjects.
1996 Aug
The effect of inhaled thiorphan on allergen-induced airway responses in asthmatic subjects.
1996 May
Inhibition of opioid-degrading enzymes potentiates delta9-tetrahydrocannabinol-induced antinociception in mice.
1998
Ecadotril. (S)-acetorphan, sinorphan.
1999 Apr
Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor GW796406.
2005 Dec
Neutral endopeptidase (EC 3.4.24.11) in cirrhotic liver: a new target to treat portal hypertension?
2005 Nov
Thiorphan, a neutral endopeptidase inhibitor used for diarrhoea, is neuroprotective in newborn mice.
2006 Dec
Neprilysin participates in skeletal muscle regeneration and is accumulated in abnormal muscle fibres of inclusion body myositis.
2006 Feb
Synergy between natriuretic peptides and phosphodiesterase 5 inhibitors ameliorates pulmonary arterial hypertension.
2008 Oct 15
Role of mu- and delta-opioid receptors in the nucleus accumbens in cocaine-seeking behavior.
2009 Jul
A comprehensive review of the pharmacodynamics, pharmacokinetics, and clinical effects of the neutral endopeptidase inhibitor racecadotril.
2012
Patents

Sample Use Guides

50 to 400 mg twice daily
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Wed Apr 02 18:03:52 GMT 2025
Edited
by admin
on Wed Apr 02 18:03:52 GMT 2025
Record UNII
XJ8Z52GK3X
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
Thiorphan, (S)-
Common Name English
LY-171436
Preferred Name English
(+)-Thiorphan
Common Name English
Glycine, N-[(2S)-2-(mercaptomethyl)-1-oxo-3-phenylpropyl]-
Systematic Name English
N-[(2S)-2-(Mercaptomethyl)-1-oxo-3-phenylpropyl]glycine
Systematic Name English
Thiorphan, (+)-
Common Name English
(S)-Thiorphan
Common Name English
LY171436
Code English
Code System Code Type Description
FDA UNII
XJ8Z52GK3X
Created by admin on Wed Apr 02 18:03:52 GMT 2025 , Edited by admin on Wed Apr 02 18:03:52 GMT 2025
PRIMARY
CAS
95909-00-5
Created by admin on Wed Apr 02 18:03:52 GMT 2025 , Edited by admin on Wed Apr 02 18:03:52 GMT 2025
PRIMARY
PUBCHEM
4369380
Created by admin on Wed Apr 02 18:03:52 GMT 2025 , Edited by admin on Wed Apr 02 18:03:52 GMT 2025
PRIMARY
Related Record Type Details
RACEMATE -> ENANTIOMER
ENANTIOMER -> ENANTIOMER
Related Record Type Details
PRODRUG -> METABOLITE ACTIVE
Related Record Type Details
ACTIVE MOIETY